Intech Investment Management LLC Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

Intech Investment Management LLC purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,797 shares of the company’s stock, valued at approximately $714,000.

Several other hedge funds and other institutional investors also recently modified their holdings of TWST. Signaturefd LLC lifted its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares in the last quarter.

Wall Street Analyst Weigh In

TWST has been the topic of several research reports. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday. Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Evercore ISI boosted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Finally, Barclays cut their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Insider Activity

In other news, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. This represents a 0.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emily M. Leproust sold 14,334 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the transaction, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock worth $4,391,151 in the last 90 days. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Up 1.8 %

NASDAQ TWST opened at $49.18 on Friday. The stock’s 50-day moving average price is $43.78 and its two-hundred day moving average price is $46.23. The company has a market cap of $2.92 billion, a PE ratio of -13.42 and a beta of 1.78. Twist Bioscience Co. has a 1 year low of $23.25 and a 1 year high of $60.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.